204 related articles for article (PubMed ID: 11599338)
1. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Vu D; Macdonald L
CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
[No Abstract] [Full Text] [Related]
2. [Comprehensive view of hepatitis and the other reactions secondary to antituberculosis chemotherapy].
Girling DJ
Bull Int Union Tuberc; 1980; 55(1-2):9-13. PubMed ID: 7214064
[No Abstract] [Full Text] [Related]
3. Antituberculosis drugs and hepatotoxicity.
Sharma SK
Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
[No Abstract] [Full Text] [Related]
4. [Toxicity of antitubercular agents for the liver].
Dölle W
Dtsch Med Wochenschr; 1973 Jan; 98(2):74. PubMed ID: 4683834
[No Abstract] [Full Text] [Related]
5. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Ijaz K; McElroy PD; Navin TR
Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
[No Abstract] [Full Text] [Related]
6. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
7. [Fulminant hepatic failure due to tuberculostatic drugs: case report].
Malla I; Fauda M; Casanueva E; Fernández MI; Amante M; Cheang Y; Giacove G; Pedreira A; Petracca P; González Campaña A; Silva M; Podestá G
Arch Argent Pediatr; 2012; 110(3):e35-8. PubMed ID: 22760756
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
9. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Chang KC; Leung CC
Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
[No Abstract] [Full Text] [Related]
10. [Clinically apparent liver damage during brief tuberculosis therapy].
Estay S; Armas Merino R; Vega C; Soto JR
Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
[No Abstract] [Full Text] [Related]
11. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
Cook PP
Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
[No Abstract] [Full Text] [Related]
12. [Isoniazid-induced hepatic failure. Report of a case].
Pereira RM; Tresoldi AT; Hessel G
Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
[TBL] [Abstract][Full Text] [Related]
13. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
[TBL] [Abstract][Full Text] [Related]
14. [Fulminant hepatitis during the therapy for tuberculous meningitis].
Garavelli PL
Recenti Prog Med; 1996 Dec; 87(12):597. PubMed ID: 9102699
[No Abstract] [Full Text] [Related]
15. Adverse effects of antituberculosis drugs.
Girling DJ
Drugs; 1982; 23(1-2):56-74. PubMed ID: 6459920
[No Abstract] [Full Text] [Related]
16. Adverse reactions to drugs used in the treatment of tuberculosis.
Nariman S
Adverse Drug React Acute Poisoning Rev; 1988; 7(4):207-27. PubMed ID: 3071113
[No Abstract] [Full Text] [Related]
17. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
Schaberg T; Rebhan K; Lode H
Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
[TBL] [Abstract][Full Text] [Related]
19. [Liver injury under tuberculostatic treatment].
Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
Burman WJ; Reves RR
Am J Respir Crit Care Med; 2001 Oct; 164(7):1112-3. PubMed ID: 11673194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
